73 related articles for article (PubMed ID: 11379564)
1. Prostate cancer screening.
Mannello F; Gazzanelli G
Lancet; 2001 Apr; 357(9263):1202. PubMed ID: 11379564
[No Abstract] [Full Text] [Related]
2. Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening?
Wolk A; Andersson SO; Mantzoros CS; Trichopoulos D; Adami HO
Lancet; 2000 Dec; 356(9245):1902-3. PubMed ID: 11130391
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer screening.
Stattin P; Stenman UH; Riboli E; Hallmans G; Kaaks R
Lancet; 2001 Apr; 357(9263):1202-3. PubMed ID: 11332426
[No Abstract] [Full Text] [Related]
4. Regulatory mechanisms in prostate cancer.
Jefferson K; Dwivedi A; Persad R; Holly J
Lancet; 2000 Mar; 355(9209):1100-1. PubMed ID: 10744117
[No Abstract] [Full Text] [Related]
5. Inverse relation between prostate-specific antigen and insulin-like growth factor-binding protein 3 in bone metastases and serum of patients with prostate cancer.
Smith GL; Doherty AP; Mitchell H; Hanham IW; Christmas TJ; Epstein RJ
Lancet; 1999 Dec; 354(9195):2053-4. PubMed ID: 10636379
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer screening.
Finne P; Auvinen A; Stenman UH
Lancet; 2001 Apr; 357(9263):1201; author reply 1201-2. PubMed ID: 11330269
[No Abstract] [Full Text] [Related]
7. Making sense of PSA.
Thompson IM
Health News; 2001 Apr; 7(4):3. PubMed ID: 11303477
[No Abstract] [Full Text] [Related]
8. Prostate cancer screening.
Ablin AJ
Lancet; 2001 Apr; 357(9263):1201-2; author reply 1201-2. PubMed ID: 11332425
[No Abstract] [Full Text] [Related]
9. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
[TBL] [Abstract][Full Text] [Related]
10. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.
Nam RK; Trachtenberg J; Jewett MA; Toi A; Evans A; Emami M; Narod SA; Pollak M
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1270-3. PubMed ID: 15894684
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a prospective multiethnic study.
Borugian MJ; Spinelli JJ; Sun Z; Kolonel LN; Oakley-Girvan I; Pollak MD; Whittemore AS; Wu AH; Gallagher RP
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):252-4. PubMed ID: 18199733
[No Abstract] [Full Text] [Related]
12. [Insulin-like growth factor (IGF-1) and the clinical course of prostate cancer, benign hyperplasia and prostatic intraepithelial neoplasia].
Povelitsa EA; Nabyrov EA
Vopr Onkol; 2008; 54(5):596-601. PubMed ID: 19069473
[TBL] [Abstract][Full Text] [Related]
13. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
[TBL] [Abstract][Full Text] [Related]
14. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
Miyata Y; Sakai H; Hayashi T; Kanetake H
Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?
Jackson BR
Arch Pathol Lab Med; 2013 Mar; 137(3):308-9. PubMed ID: 22799565
[No Abstract] [Full Text] [Related]
16. [Opportunity for a systematic screening of prostatic cancer by determining prostate specific antigen levels].
Cuzin B; Maisonneuve H; Thoral F; Charvet-Protat S
Prog Urol; 2000 Feb; 10(1):124-7. PubMed ID: 10785932
[No Abstract] [Full Text] [Related]
17. [Insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) as serum markers of prostate cancer].
Matsubara A; Nakamoto T; Usui T
Nihon Rinsho; 2000 Jul; 58 Suppl():157-62. PubMed ID: 11022706
[No Abstract] [Full Text] [Related]
18. Prostate-specific antigen screening for prostate cancer: why so much controversy?
Labrie F
Int J Urol; 2013 Nov; 20(11):1148. PubMed ID: 23586435
[No Abstract] [Full Text] [Related]
19. Upcoming evidences on prostate-specific antigen-based screening for men at risk of prostate cancer.
Boscolo-Berto R
Int J Urol; 2009 Sep; 16(9):711. PubMed ID: 19769655
[No Abstract] [Full Text] [Related]
20. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
Zhigang Z; Jieming L; Su L; Wenlu S
J Surg Oncol; 2007 Jul; 96(1):54-61. PubMed ID: 17345593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
